Vaccitech Newsroom
News & updates
Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
Oxford, UK - Vaccitech Ltd announces that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK. The vaccine was...
First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy
Oxford, UK - Vaccitech’s scientific founders at University of Oxford and Astrazeneca announce the first peer-reviewed publication of Phase 3 data from studies of a vaccine against the coronavirus in the Lancet. The vaccine, ChAdOx1 nCoV-19, also known as AZD1222, was...
Vaccitech Chief Scientific Officer Dr. Thomas Evans on COVID-19 vaccination
In an interview with Sky News, Vaccitech Chief Scientific Officer, Dr. Thomas Evans, discusses the regulatory and public health aspects of Emergency Use Authorisation of COVID-19 vaccines. The interview aired on the 2nd of December 2020.
Vaccitech Co-Founder Professor Adrian Hill on Developing a Covid-19 Vaccine
Following the news that AstraZeneca, the University of Oxford, and Vaccitech's vaccine for COVID-19 is highly effective and safe, Vaccitech co-founder Professor Adrian Hill talked to Tom Hulme, General Partner at Vaccitech shareholder GV, Vidu Shanmugarajah, Partner...
Oxford University breakthrough on global COVID-19 vaccine
Oxford, UK - Vaccitech’s scientific founders at University of Oxford announce positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil. Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is...
Oxford coronavirus vaccine produces strong immune response in older adults
Vaccitech Ltd, a clinical-stage biopharmaceutical company developing vaccines and immunotherapies to treat and prevent infectious diseases and cancer, announces that the ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been...
Vaccitech expands management team with hires including CMO and CFO
Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing T cell vaccines and immunotherapies designed to treat and prevent infectious disease and cancer, today announces the appointment of three new senior leaders across its clinical,...
University of Oxford and Vaccitech to present at the ESMO Virtual Congress
Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, today announces that results from ADVANCE, a Phase 1/2 study in metastatic castrate resistant prostate cancer...
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups Vaccitech Ltd, a clinical-stage...
Vaccitech receives government grant for COVID-19 vaccine research
Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation...